Amrize Insiders Accumulate Stock Even as Brokerages Retreat and Shares Linger Near Lows
Published on 08/29/2026 at 18:33 | Editorial boerse-global.de
The divergence could hardly be starker. Wall Street has spent the past month trimming price targets and downgrading Amrize, yet the building materials group's own executives keep opening their wallets for the company's equity. That insider buying, however, has done little to arrest a slide that has left the stock trading barely above its 52-week low.
Shares closed Friday at €38.68, up 1.7% on the day, but the bounce does little to mask the broader damage. The stock remains down 11% over the past month and has shed 18% since the start of the year. At current levels, the shares sit just 3.1% above the 52-week trough of €37.50, a low touched only on August 25, while they remain roughly 31% below February's peak.
A Second-Quarter Miss That Keeps Haunting the Stock
The selling pressure traces back to the company's second-quarter report, which delivered a top-line beat but fell short where it mattered most to investors. Revenue climbed 8.6% to $3.494 billion, and net income advanced 14.4% to $476 million. Adjusted earnings per share of $0.88, however, came in below the consensus estimate of $0.95.
The margin story was the real disappointment. Adjusted EBITDA rose 5.8% to $986 million, missing analyst expectations of roughly $1.010 billion, and the 28.2% EBITDA margin came in well under the 30.0% that brokers had penciled in. Management pointed to $75 million in oil-price-driven cost pressures across freight, diesel and raw materials, which dragged adjusted EBITDA down 5.2% in the Building Envelope segment.
The Building Materials unit, by contrast, delivered a solid performance, with revenue up 8.2%, cement volumes growing 5% and aggregates advancing 6.5%. The company also lifted its full-year revenue guidance to a range of $12.5 billion to $12.7 billion, up from a prior target of $12.29 billion to $12.52 billion. Its ASPIRE cost-saving program contributed $29 million during the quarter and is expected to deliver $250 million cumulatively by 2028.
That brighter outlook, though, was overshadowed by the margin weakness — and by a subsequent restatement. Amrize had to make corrections to earlier financial reports related to the deferral of extended warranty revenue from its acquisitions of Duro-Last and Malarkey, adjustments the company characterized as immaterial.
When companies face restatements and compliance scrutiny, it's a reminder that getting documentation right matters. For workplace safety, the same principle applies — a single missing risk assessment can expose your business to serious liability. A free toolkit with 41 ready-to-use templates and checklists helps you document hazards properly and stay compliant. Download the free Risk Assessment Toolkit
Brokerages Turn Cautious in Rapid Succession
The analyst community responded to the results with a wave of caution that has yet to fully subside. RBC Capital downgraded the stock to Underperform from Sector Perform on August 10, slashing its price target from $60 to $48 and trimming earnings estimates for 2026 through 2028 by as much as 15%. Citi followed the same day, lowering its target from $66 to $58.
The cuts kept coming. Stephens reduced its target to $54 from $65 on August 15 while maintaining a Buy rating, and Bank of America trimmed to $50 from $60 on August 18. Truist also moved to Hold with a $48 target. Midweek brought two fresh, more guarded assessments: DA Davidson initiated coverage with a Neutral rating and a $50 price target on August 24, citing limited visibility into positive catalysts amid ongoing margin uncertainty, and UBS launched coverage the following day with a Hold recommendation.
Not everyone has turned bearish. JPMorgan and Deutsche Bank have held firm with Overweight and Buy ratings respectively, and both even nudged their price targets slightly higher in Swiss francs.
Management Buys, Pays Dividends and Reshuffles Leadership
Against that backdrop, insiders have been consistent buyers. On Wednesday, Director Jacques Wolf Sanchez purchased shares worth $186,833. Earlier in the month, on August 11, Jaime Hill, President of the Building Materials segment, acquired 1,500 shares at $47.12, while Chief People Officer Stephen S. Clark bought 5,260 shares at $47.31. Board-level purchases in Swiss francs also took place in mid-August, most recently at CHF 37.97 per share.
The buying coincides with an ongoing buyback program. Amrize deployed $197 million on share repurchases in the second quarter under a multi-billion-dollar authorization that runs through May 2027, and paid a quarterly dividend of $0.11 per share. Combined shareholder returns for the quarter reached $502 million. The most recent dividend was paid on Wednesday, with the shares trading ex-dividend from August 18.
There has also been movement in the executive suite. Samuel J. Poletti took over as Chief Financial Officer on August 24, succeeding Baris Oran, who resigned for personal reasons. Poletti previously served as Chief Strategy and M&A Officer, where he helped steer the spin-off from Swiss cement giant Holcim in June 2025, and he arrives with deep familiarity with both the ASPIRE cost program and the integration of Rapid Redi-Mix, the Texas-based concrete producer whose acquisition was agreed in July.
Investors will get their next read on the company when second-half results are due on November 3, an update that should show whether the Dallas-Fort Worth acquisition is beginning to contribute.
